Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Hospira Inc., a Pfizer company announced recall of several injectable products in US for potential glass particulates in vials.
Three of the products recalled are 4.2% Sodium Bicarbonate Injection (NDC 0409-5534-24); 8.4% Sodium Bicarbonate Injection (NDC 0409-6637-24); Atropine Sulfate Injection (NDC 0409-4911-11). The recalls were initiated due to the potential for presence of glass particulate matter, identified during product inspection. Another recall of Bleomycin for Injection (NDC 61703-332-18) was initiated due to a confirmed customer report for the presence of glass particulate within a single vial of the product.
Recall Intimation Bleomycin for Injection
Leave a Comment
You must be logged in to post a comment.